The median duration of venetoclax treatment differed quite a bit from the recommended fixed-duration dosing schedules, according to a study presented at the 2023 National Comprehensive Cancer Network Annual Meeting in Orlando, Florida. Venetoclax is a BH3-mimetic that blocks the B-cell lymphoma-2 (Bcl-2) protein. It treats first-line and relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). For first-line therapy, venetoclax is given with obinutuzumab in a 12-cycle (12-month) regimen. For relapsed/refractory CLL, venetoclax is combined with ...
NCCN 2023 Annual Conference: Focus on CLL
The 2023 National Comprehensive Cancer Network Annual Conference allows network members to attend interactive educational sessions and engaging poster presentations, as well as to meet and exchange ideas with colleagues. The conference was held from March 31 through April 2 in Orlando, Florida. This year, the editors at Cancer Nursing Today focused on chronic lymphocytic leukemia research and have brought you the most recent news and developments in the disease’s treatment and outcomes.
Advertisement
Though rare, CLL and CML sometimes occur sequentially or concurrently. But what is the mechanism behind the relationship?
In a currently enrolling trial, patients with CLL and NMSC will receive experimental treatment with nicotinamide.
Deborah Stephens, DO, presented the recommendations and algorithms for first-, second-, and third-line CLL/SLL therapy.
Advertisement
